Nyrada Inc. (NYR.AX)
AUD 0.1
(-2.0%)
AUD 0.1
(-2.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -5164.07 AUD | -100.36% |
| 2023 | 1.42 Million AUD | 30.7% |
| 2022 | 1.08 Million AUD | -53.35% |
| 2021 | 2.33 Million AUD | 107.68% |
| 2020 | 1.12 Million AUD | 131.77% |
| 2019 | 484.93 Thousand AUD | 407605.88% |
| 2018 | -119.00 AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | -2321.21 AUD | 0.0% |
| 2024 FY | -5164.07 AUD | -100.36% |
| 2024 Q2 | 2.45 Million AUD | 0.0% |
| 2023 FY | 1.42 Million AUD | 30.7% |
| 2023 Q2 | 952.07 Thousand AUD | 0.0% |
| 2023 Q4 | 471.26 Thousand AUD | 0.0% |
| 2022 Q4 | 1.08 Million AUD | 0.0% |
| 2022 FY | 1.08 Million AUD | -53.35% |
| 2022 Q2 | 2856.18 AUD | 0.0% |
| 2021 Q4 | 2.28 Million AUD | 0.0% |
| 2021 FY | 2.33 Million AUD | 107.68% |
| 2021 Q2 | 50.86 Thousand AUD | 0.0% |
| 2020 FY | 1.12 Million AUD | 131.77% |
| 2020 Q4 | 1.12 Million AUD | 0.0% |
| 2020 Q2 | -706.00 AUD | 0.0% |
| 2019 Q2 | -682.16 Thousand AUD | -100.0% |
| 2019 Q4 | 127.3 Thousand AUD | 0.0% |
| 2019 FY | 484.93 Thousand AUD | 407605.88% |
| 2019 Q1 | -341.08 Thousand AUD | 0.0% |
| 2018 FY | -119.00 AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 100.01% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 99.31% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | 150.215% |
| Biome Australia Limited | 7.66 Million AUD | 100.067% |
| Patrys Limited | 1.39 Million AUD | 100.37% |
| Orthocell Limited | 3.68 Million AUD | 100.14% |
| Imugene Limited | -5.83 Million AUD | 99.912% |
| Noxopharm Limited | -534.81 Thousand AUD | 99.034% |
| PYC Therapeutics Limited | 22.05 Million AUD | 100.023% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 100.069% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 100.139% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 99.54% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 100.223% |
| CSL Limited | 15.28 Billion AUD | 100.0% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 80.122% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 98.287% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 100.007% |
| Starpharma Holdings Limited | 7.65 Million AUD | 100.067% |
| Nanollose Limited | -348.95 Thousand AUD | 98.52% |
| Memphasys Limited | 1606.00 AUD | 421.549% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 100.426% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 94.346% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 100.129% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 99.921% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 100.413% |
| Race Oncology Limited | 1.38 Million AUD | 100.372% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 100.002% |
| Dimerix Limited | 583.47 Thousand AUD | 100.885% |
| PharmAust Limited | -1641.00 AUD | -214.69% |
| Immutep Limited | 1.44 Million AUD | 100.358% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 100.045% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 100.136% |
| BTC Health Limited | 16.36 Thousand AUD | 131.565% |
| Acrux Limited | -1.28 Million AUD | 99.598% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 100.003% |
| Biotron Limited | -40.49 Thousand AUD | 87.249% |
| Tissue Repair Ltd | 150.51 Thousand AUD | 103.431% |
| AdAlta Limited | 1.5 Million AUD | 100.342% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 99.976% |
| Hexima Limited | - AUD | Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | 101.122% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 109.09% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 98.592% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 88.209% |
| Actinogen Medical Limited | 9.93 Million AUD | 100.052% |
| Immuron Limited | 3.33 Million AUD | 100.155% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 100.199% |